secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001104659-23-014934
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune Q3 net loss $39.7M; cash $616M; RP1 melanoma achieves 36% ORR in IGNYTE cohort
--------------------------------------------------------------------------------

- Net loss $39.7M for fiscal Q3 ended Dec 31, 2022 vs $29.7M YoY; R&D expenses rose to $30.3M.
- Raised ~$259M gross in upsized public offering; secured $200M non-dilutive debt facility ($30M drawn); cash runway into H2 2025.
- Topline data from CERPASS trial (RP1+cemiplimab in CSCC) delayed to Q3 2023 from prior H1 2023.
- IGNYTE cohort of RP1+Opdivo in anti-PD1 failed melanoma: 36% ORR, 20% CR in first 75 patients; target enrollment of 125 reached.
- Collaboration with Roche for RP2/3 in CRC and HCC; appointed Christopher Sarchi as CCO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465923014934/0001104659-23-014934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465923014934/tm235946d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-014934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer